

In conclusion: Omran's 'epidemiologic transition' has been a useful heuristic device, but should no longer be taken too seriously.

Ethics approval

Not required.

Acknowledgements

This reflection is partly based on Chapters 1 and 7 of my recent book, *A History of Population Health; Rise and Fall of Disease in Europe* (Brill|Rodopi, 2020). This open access publication, which contains extensive references, can be downloaded at: [https://brill.com/view/title/571111].

Conflict of interest

None declared.

References

1. Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. *Milb Mem Fund Q* 1971;49:509–38.
2. Mackenbach JP. *A History of Population Health. Rise and Fall of Disease in Europe*. Leiden, The Netherlands, and Boston, MA: Brill|Rodopi, 2020.
3. Omran AR. The epidemiologic transition theory. A preliminary update. *J Trop Pediatr* 1983;29:305–16.
4. Mackenbach JP. The epidemiologic transition theory. *J Epidemiol Community Health* 1994;48:329–32.
5. Frenk J, Bobadilla JL, Stern C, Frejka T, Lozano R. Elements for a theory of the health transition. *Health Transit Rev* 1991;1:21–38.
6. Sanders JW, Fuhrer GS, Johnson MD, Riddle MS. The epidemiological transition: the current status of infectious diseases in the developed world versus the developing world. *Sci Prog* 2008;91:1–37.
7. Caselli G, Meslé F, Vallin J. Epidemiologic transition theory exceptions. *Genus* 2002;58:9–51.
8. Olshansky SJ, Ault AB. The fourth stage of the epidemiologic transition: the age of delayed degenerative diseases. *Milb Q* 1986;64:355–91.
9. Olshansky SJ, Carnes BA, Rogers RG, Smith L. Emerging infectious diseases: the fifth stage of the epidemiologic transition? *World Health Stat Q* 1998;51:207–17.
10. Barrett R, Kuzawa CW, McDade T, Armelagos GJ. Emerging and re-emerging infectious diseases: the third epidemiologic transition. *Annu Rev Anthropol* 1998;27:247–71.
11. Salomon JA, Murray CJ. The epidemiologic transition revisited: compositional models for causes of death by age and sex. *Popul Dev Rev* 2002;28:205–28.
12. Omran AR. The epidemiologic transition theory revisited thirty years later. *World Health Stat Q* 1998;51:99–119.

Large variation in the epidemiological transition across countries: is it still valuable as a mortality theory?

Nikkil Sudharsanan,^{1,2*} José Manuel Aburto,^{3,4} Tim Riffe ^{5,6,7} and Alyson van Raalte ⁷

¹Professorship of Behavioral Science for Disease Prevention and Health Care and Institute for Advanced Study, Technical University of Munich, Munich, Germany, ²Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany, ³Leverhulme Centre for Demographic Science, Department of Sociology and Nuffield College, University of Oxford, Oxford, UK, ⁴Interdisciplinary Centre on Population Dynamics, University of Southern Denmark, Odense, Denmark, ⁵OPIK, Departamento de sociología y Trabajo Social, Universidad del País Vasco (UPV/EHU), Leioa, Spain, ⁶Ikerbasque, Basque Foundation for Science, Bilbao, Spain and ⁷Max Planck Institute for Demographic Research, Rostock, Germany

*Corresponding author. Professorship of Behavioral Science for Disease Prevention and Health Care and Institute for Advanced Study, Technical University of Munich, 60-62 Georg-Brauchle-Ring, 80992 Munich, Germany. E-mail: nikkil.sudharsanan@tum.de

Received 23 February 2022; Editorial decision 19 April 2022; Accepted 2 May 2022

International Journal of Epidemiology, 2022, 1057–1061

<https://doi.org/10.1093/ije/dyac107>

Advance Access Publication Date: 26 May 2022

Reprints and Reflections

OXFORD

Omran's epidemiological transition is one of the main theories of global mortality change. In his initial paper, Omran¹ outlined a broad model that sought to link epidemiological and social factors with the demographic transition theory—the major population theory which described population growth as arising from the lag between declines in death and birth rates, while population age structures transitioned from young to older.^{2,3} Omran sought to draw a deeper focus on the mortality determinants of demographic transition, which had received comparably less attention than the determinants of fertility decline.⁴

In this way, Omran classified human populations into distinct stages, each characterized demographically (levels and volatility of death rates, fertility rates, and population growth rates) and epidemiologically (cause-of-death contributions). His initial paper had three 'Ages' (the age of pestilence and famine, the age of receding pandemics and the age of degenerative and man-made diseases), and Omran himself later expanded this to include the age of declining cardiovascular mortality, ageing, lifestyles modification and emerging and resurgent diseases, and a fifth yet-unrealized age of aspired quality of life.⁵ The core theoretical value of the epidemiological transition is that, given some information on the level of mortality in a population (such as life expectancy at birth), we should be able to meaningfully infer a host of current and future population characteristics including growth and fertility rates and cause-of-death profiles.

But does the theory really provide accurate inferences? If we focus just on the relationship between level of life expectancy and cause-of-death profiles, an immediate challenge is that the theory is presented deterministically across the four stages: between Stages 1 and 3, populations transition from low life expectancy and mortality regimes dominated by infectious mortality primarily among children, to regimes dominated by cardiovascular diseases. Between Stages 3 and 4, life expectancy continues to increase to levels above 75 years, with cardiovascular mortality leveling off and starting to decline. Whereas Omran's initial model distinguished between different variants of the epidemiological transition, these variants differed primarily on the pace and social-technological mechanisms driving transitions between the different stages, not on the variations of the stages themselves.

What has remained elusive, is whether there is high within-stage variation in the evolution of causes of death among different populations and across sexes, which might undermine the predictive power of the theory. For the theory to be useful, it should be able to guide predictions that inform health priorities. For example, it should predict cause-of-death profiles in countries with incomplete cause-of-death statistics, or guide predictions of how causes of

death will evolve in the future. Otherwise, the epidemiological transition theory should be relegated to a stylized description of a transition that took place in a handful of early-industrializing countries.

Whereas few countries have accurate cause-of-death data at low life expectancies, we can reliably observe the epidemiological transition between the ages of 'degenerative and man-made diseases' and 'declining cardiovascular mortality, aging and emerging and resurgent diseases' in several world regions (see [Supplementary Appendix](#) for data and methods, available as [Supplementary data](#) at *IJE* online). This can tell us if there is actually a universal path to low mortality.

Relationship between life expectancy at birth and the burden of each cause group by sex

In [Figure 1](#) we graph, at each life expectancy level, the mortality burden by broad cause-of-death groupings. We operationalize 'burden' as the potential years of life expectancy gained by total elimination of a group of causes, estimated using cause-deleted life table methodology. This measure has the advantages of more strongly weighting causes of death at ages with more remaining life-years and of providing comparable burden estimates across regions and over time.⁶

We observe broad trends consistent with the epidemiological transition theory: for both sexes and every country, cardiovascular diseases carried the largest mortality burden for the majority of the transition between a life expectancy of 65 and 80, with a declining role for infant and child mortality. However, the magnitude of cause burdens when countries were at similar historical levels of life expectancy was not universal—especially for cardiovascular disease mortality. For example, at a life expectancy of 75, cardiovascular diseases carried a burden of 16 potential years of life expectancy among Australian women compared with just 2.5 years among South Korean men. We also observe a substantial, and sometimes even increasing, burden of infectious disease mortality in some countries that were already in advanced stages of the transition when life expectancy is high. This finding conflicts with the epidemiological transition, which postulates that the impact of infant and infectious disease mortality should be negligible at these levels of life expectancy.

Beyond this individual country variation, there was also important variation by sex. Compared with men, women had a consistently higher burden of infant mortality at all life expectancy levels, a higher and later peak in the burden of cardiovascular disease mortality and a lower burden of external and cancer mortality.




Figure 1 Relationship between life expectancy at birth and the mortality burden of each cause of death. ^aWe estimated life expectancy gained as the change in life expectancy at birth between the observed and cause-deleted life table for each cause separately. ^bThe individual lines are the country-specific series; the bold lines are the loess smoothing lines. ^cInfant mortality is deaths from all causes between ages 0–1; child mortality is deaths from all causes between ages 1–5, and infectious disease mortality here is only among those aged 5+

Regional differences in the relationship between life expectancy at birth and the burden of each cause group

A large part of the across-country variation we observed in [Figure 1](#) is largely structured by geographical regions—especially for women ([Figure 2](#)). We observed substantially higher burdens of cardiovascular disease mortality in North America and Oceania and a conversely low burden in Southern Europe and Asia. Similarly, we observe substantially lower burdens of cancer mortality in both Southern Europe and Asia relative to the other three regions. There is also important variation in infant and infectious disease mortality. Southern Europe had the highest burden of infant mortality across every level of life expectancy whereas Asia held the highest burden of infectious mortality at most life expectancies.

What does the epidemiological transition mean for low- and middle-income countries?

Without high-quality data from a broad set of countries, it is challenging to assess the accuracy of Omran's depiction of high-mortality populations in either the past or the present. But it is reasonable to assume that some combination of infectious disease, famines and war kept death rates high, and that countries transitioning to a low-mortality profile would do so with a substantial transformation in the age and cause-of-death distribution; but as countries enter advanced stages of the transition, as shown here, it becomes more difficult to accurately characterize mortality profiles.

This is important because it defies the value of the epidemiological transition to estimate and predict cause-of-death mortality levels in contexts where this information is




Figure 2 Relationship between life expectancy at birth and the burden of each cause, separately by region. ^aWe estimated life expectancy gained as the change in life expectancy at birth between the observed and cause-deleted life table for each cause separately. ^bThe individual lines are the country-specific series; the bold lines are the loess smoothing lines. ^cWe only show smoothed trends for life expectancy levels where there are data for at least three countries within the region, with the exception of the Asian region which just has Japan and South Korea ^dWe show each cause with a different y-axis to ensure that the variation is visible. As such, these graphs are not meant for a comparison of the contributions across causes but rather within causes

needed now for policy, such as in low- and middle-income countries (LMICs). Moreover the increased global heterogeneity in mortality profiles, combined with emerging infectious diseases in many LMICs, suggest that the epidemiological transition will fail to appropriately characterize cause-of-death mortality in these countries, casting further doubt on its value in LMICs. Omran's own interpretation of transition in LMICs is problematic and embodies offensive tropes, particularly in his 1998 publication, including for example that 'internationally sponsored' medical efforts were the source of mortality decline in these countries and that high fertility 'was considered the proof of a woman's fecundity and a man's virility'.⁵

We find that the later phases of the epidemiological transition are far from universal, even among a relatively small set of now high-income countries. Whereas the broad stylized facts of the relationship between life expectancy and causes of death are consistent across countries—a high burden of cardiovascular mortality starting as low as a life expectancy of 65, a declining burden of infant and child mortality and a steadily increasing burden of cancers—we observe a tremendous amount of variation beyond these stylized facts, structured strongly by sex and geographical region. Importantly, our results only apply to the later stages of the epidemiological transition and do not directly contradict or invalidate the earlier, more classical, stages

of the epidemiologic transition. However in prior work, Preston and Nelson (1974) take a similar approach to ours, using data from 1861 to 1964—when many countries were still in the classical stages of the epidemiological transition—and similarly find evidence of large variation in the burden of different causes of death across countries at similar levels of all-cause mortality.⁷

There are multiple epidemiological paths to low mortality, and the cause-of-death compositions of these transitions are too variable at higher life expectancies to be summarized in deterministic stages.

Ethics approval

This study was exempt from ethical approval since it uses aggregated, publicly available mortality data.

Data availability

All data are freely available and automatically downloaded using the code deposited in an Open Science Framework (OSF) reproducibility repository [https://osf.io/vwd37/?view_only=8e1a9f4ab1f642a7a811b199ab0e27b5].

Supplementary data

[Supplementary data](#) are available at *IJE* online.

Author contributions

Data analysis and visualization: N.S. and T.R.

Writing and reviewing the manuscript: N.S., A.vR., T.R., J.M.

Funding

N.S. received funding from the Alexander von Humboldt Foundation. J.M. received funding from the British Academy's Newton International Fellowship (NIFBA19/190679). A.vR. received funding from European Research Council (716323).

Conflict of interest

None declared.

References

1. Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. *Milbank Mem Fund Q* 1971;**49**:509–38.
2. Davis K. The world demographic transition. *Ann Am Acad Pol Soc Sci* 1945;**237**:1–11.
3. Kirk D. Demographic transition theory. *Popul Stud (Camb)* 1996; **50**:361–87.
4. Caldwell JC. Population health in transition. *Bull World Health Organ* 2001;**79**:159–60.
5. Omran AR. The epidemiologic transition theory revisited thirty years later. *World Health Stat Q* 1998;**53**:99–119.
6. Beltrán-Sánchez H, Preston SH, Canudas-Romo V. An integrated approach to cause-of-death analysis: cause-deleted life tables and decompositions of life expectancy. *Demogr Res* 2008;**19**: 1323.
7. Preston SH, Nelson VE. Structure and change in causes of death: an international summary. *Popul Stud (Camb)* 1974;**28**: 19–51.